N6-methylandenosine-related lncRNAs have the prognostic predictive ability for patients with Endometrial Cancer

Abstract

Abstract Endometrial carcinoma (EC) is the fourth most common cancer with increasing morbidity and mortality in recent years. Therefore, it’s urgent and crucial to identify potential reliable biomarkers as useful therapeutic targets for the prognosis of EC patients. In this study, we screened 1,560 m6A-related lncRNAs through Pearson correlation coefficient based on the Cancer Genome Atlas (TCGA) datasets and the GENCODE annotation. Based on the univariate Cox regression analysis, we identified 187 m6A-related lncRNAs related to the prognosis of EC patients. Based on the LASSO Cox analysis, twelve m6A-related prognostic lncRNAs were used to construct a m6A-related lncRNA prognostic signature (m6A-LPS). Our results indicated that the m6A-LPS had a robust prognostic ability and the constructed nomogram (based on m6A-LPS, age, and pathological grade) had great ability to predict the OS of EC patients. Through comparing the differences of tumor-infiltrating immune cells between high-risk and low-risk groups (based on the median value of risk score), we found that EC patients in low-risk group had higher immune cell infiltration and lower tumor purity. Furthermore, we constructed a competing endogenous RNA (ceRNA) network which was used to reveal potential function of those m6A-related prognostic lncRNAs. In general, we established the m6A-LPS, which had stable and robust ability to predict the OS of EC patients. Our study might contribute to the identification of reliable biomarkers as therapeutic targets for the prognosis of EC and provide novel insights into the mechanism of pathogenesis of EC.